Board to approve September 2026 quarter and half-year results

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.1%Reaction day

₹10.65

prior close

₹11.06

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+5.0% vs market

Pharmaceuticals peers, median of 170sector+0.6%+4.5% vs sector

On the reaction day the stock moved 5.0 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.5

15m

-0.5

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.1+0.1+5.0+0.6+4.5

Next day

+6.3+0.7+5.6+1.1+5.2

+3.4-1.8+5.2-0.3+3.6

+5.1-0.4+5.4+0.0+5.1

+5.1-0.1+5.2+0.4+4.6

+5.1+2.1+3.0+1.5+3.6

———+2.2—

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board will meet on 5 November 2026 to consider and approve the company's unaudited financial results for the quarter and half-year ended 30 September 2026. The notice provides no financial figures and does not report any auditor change.

Likely market impact

Only the results date is announced. No results are available yet, so the filing does not establish a positive or negative effect on the stock.

By the numbersStandalone · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹5.82 Cr	₹1.58 Cr	+269.2%
Operating profit	₹0.95 Cr	₹0.03 Cr	+2,836.0%
Profit after tax	₹0.73 Cr	₹0.07 Cr	+974.5%
EBITDA margin	17.8%	2.1%	+15.7 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.